Reports for APOTEX INC
Company Name APOTEX INC |
||
|---|---|---|
Totals |
||
Shortage reports |
3367 |
|
| Actual shortage: | 219 (7%) | |
| Anticipated shortage: | 0 (0%) | |
| Avoided shortage: | 10 (0%) | |
| Resolved: | 3138 (93%) | |
Discontinuation Reports |
365 |
|
| To be discontinued: | 24 (7%) | |
| Discontinued: | 341 (93%) | |
| Reversed: | 0 (0%) | |
Late reports |
144 (4%) |
|
Overdue reports |
68 (28%) |
|
Shortage reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| MIDODRINE | 2.5MG | TABLET | Resolved | 2017-05-11 | 2017-05-17 | 10043 |
| MIDODRINE | 2.5MG | TABLET | Resolved | 2017-10-04 | 2017-10-13 | 24363 |
| MIDODRINE | 5.0MG | TABLET | Resolved | 2017-10-13 | 2018-12-18 | 25869 |
| MIRVALA 21 | 0.1500MG 0.0300MG | TABLET | Resolved | 2018-07-04 | 2018-07-12 | 54312 |
| MIRVALA 21 | 0.0300MG 0.1500MG | TABLET | Resolved | 2022-10-21 | 2022-11-07 | 172355 |
| MIRVALA 28 | 0.0300MG 0.1500MG | TABLET | Resolved | 2024-08-22 | 2024-10-18 | 235701 |
| MIRVALA 28 | 0.1500MG 0.0300MG | TABLET | Resolved | 2019-01-30 | 2019-04-26 | 74028 |
| MIRVALA 28 | 0.1500MG 0.0300MG | TABLET | Resolved | 2018-07-04 | 2018-07-12 | 54315 |
| MIRVALA 28 | 0.0300MG 0.1500MG | TABLET | Resolved | 2022-01-14 | 2022-01-18 | 152779 |
| MYA | 0.02MG 3.00MG | TABLET | Resolved | 2023-12-15 | 2023-12-22 | 213568 |
| MYA | 0.02MG 3.00MG | TABLET | Resolved | 2024-03-08 | 2024-03-15 | 221690 |
| MYA | 0.02MG 3.00MG | TABLET | Resolved | 2023-05-26 | 2023-06-02 | 193206 |
| MYA | 0.02MG 3.00MG | TABLET | Resolved | 2025-02-20 | 2025-02-28 | 250925 |
| MYA | 0.02MG 3.00MG | TABLET | Actual shortage | 2025-05-08 | 2025-05-08 | 256899 |
| MYA | 3.00MG 0.02MG | TABLET | Resolved | 2017-03-11 | 2020-09-04 | 555 |
| MYA | 0.02MG 3.00MG | TABLET | Resolved | 2023-09-22 | 2023-10-06 | 204996 |
| ONDANSETRON | 4MG | SOLUTION | Resolved | 2017-03-13 | 2017-03-31 | 2019 |
| ONDANSETRON | 4MG | SOLUTION | Resolved | 2017-04-25 | 2018-03-14 | 7880 |
| ONDANSETRON | 4MG | SOLUTION | Resolved | 2018-12-19 | 2019-03-21 | 69959 |
| ONDANSETRON | 4MG | SOLUTION | Resolved | 2019-04-29 | 2019-08-22 | 82753 |
Discontinuation reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-BISACODYL | 5MG | TABLET (DELAYED-RELEASE) | Discontinued | 2018-09-07 | 2018-09-15 | 60288 |
| APO-BOSENTAN | 62.5MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71339 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71342 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2018-09-07 | 2018-10-31 | 60291 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2018-09-07 | 2018-12-28 | 60301 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2020-11-16 | 2020-11-16 | 128438 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | To be discontinued | 2018-09-07 | 2018-09-07 | 60294 |
| APO-BROMAZEPAM - TAB 1.5MG | 1.5MG | TABLET | To be discontinued | 2018-09-07 | 2018-09-07 | 60304 |
| APO-BROMAZEPAM - TAB 3MG | 3MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60307 |
| APO-BROMAZEPAM - TAB 6MG | 6MG | TABLET | Discontinued | 2018-09-07 | 2018-10-19 | 60310 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60313 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60316 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60325 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60322 |
| APO-CANDESARTAN | 4MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60319 |
| APO-CANDESARTAN | 32MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60328 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60335 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60331 |
| APO-CANDESARTAN/HCTZ | 25MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-05-03 | 41011 |
| APO-CANDESARTAN/HCTZ | 12.5MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41020 |